Ferring keeps looking for improved drug delivery, with new collaboration

11 April 2017

Reproductive health specialist Ferring Pharmaceuticals has entered into an agreement with German drug delivery company Alrise Biosystems to develop an injectable, controlled-release formulation of a peptide therapeutic.

Ferring, a privately-held Swiss company, has acquired exclusive option rights to leverage Alrise’s ImSus technology, a platform for engineering controlled-release formulations.

In November last year Ferring announced a collaboration with Aché Laboratórios Farmacêuticos, aimed at improving drug delivery characteristics of existing oral therapeutic medicines, through nanotechnology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK